RxDoctor Payments Data

Emily Brawner, DO

Internal Medicine · Columbus, OHNPI 1669699385

Payments from drug & device makers

$1,383in general payments, 2019–2025

Across 59 payments — averaging $23.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$621
  • GSK$223
  • AstraZeneca$119
  • Mylan Specialty L.p.$85
  • Pulmonx Corporation$76
  • Boehringer Ingelheim$61
  • plus $198 from 9 others

What the payments were for

  • Travel & lodging$18313%
  • Food & beverage$1,17485%
  • Education$262%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,383 in reported general payments places this provider in the 75th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$67,341
Medicare patients
368
Services billed
1,062

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter223$176,137
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr116$67,591
Spiriva RespimatTiotropium Bromide114$66,069
Stiolto RespimatTiotropium Br/Olodaterol Hcl92$63,160
Advair HfaFluticasone Propion/Salmeterol139$59,587
Breo ElliptaFluticasone/Vilanterol98$44,585
Breztri AerosphereBudesonide/Glycopyr/Formoterol56$41,552
Incruse ElliptaUmeclidinium Bromide68$31,088
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate82$15,566
Fluticasone-SalmeterolFluticasone Propion/Salmeterol63$11,727
Bevespi AerosphereGlycopyrrolate/Formoterol Fum22$11,600
Albuterol Sulfate HfaAlbuterol Sulfate314$9,951
SymbicortBudesonide/Formoterol Fumarate38$9,831
Arnuity ElliptaFluticasone Furoate28$9,629
Spiriva HandihalerTiotropium Bromide13$6,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta, Arnuity Ellipta$223$329,030533 claims
Boehringer IngelheimSpiriva Respimat, Stiolto Respimat$61$129,229206 claims
AstraZenecaBreztri Aerosphere, Bevespi Aerosphere, Symbicort$119$62,984116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Columbus

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →